Compare AbbVie Inc (ABBV) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Nuscale Power Corporation — how do they compare? AbbVie Inc trades at $252.44 (market cap $449.91B), while Nuscale Power Corporation trades at $9.01 (market cap $3.10B). The key difference: AbbVie Inc is far larger — about 145.1× Nuscale Power Corporation's market cap, and AbbVie Inc pays a 2.72% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| ABBV | SMR | |
|---|---|---|
Market Cap | $449.91B | $3.10B |
Sector | Health | Utilities |
52-Week High | $261.07 | $53.43 |
52-Week Low | $184.85 | $8.96 |
Enterprise Value | $513.38B | $2.21B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $251.81, down 1.16% on the day, with strong analyst support showing 68% buy ratings and a $266.33 consensus price target. The stock exhibits bullish technical momentum with recent earnings beats in Q3 2025 through Q1 2026, though Q2 2026 expectations are set at $3.79 EPS. Revenue growth remains solid with 2025 reaching $61.16B, while profitability metrics show a 70.68% gross margin offset by a thinner 5.79% net margin. Recent news highlights pipeline strength with positive Phase 2 ovarian cancer data and institutional accumulation.
The outlook for ABBV is positive driven by robust immunology drugs Skyrizi and Rinvoq offsetting Humira declines, though patent cliffs in the 2030s present long-term risks. Current valuation multiples appear elevated with P/E at 124.83 and P/B at 245.29, requiring sustained execution to justify premiums. Dividend reliability with recent $1.73 payments supports income investors, while technical resistance near $259-266 may cap near-term gains.
NuScale Power (SMR) trades at $9.61, down 1.54% on the day, reflecting ongoing bearish technical momentum. The company shows severe financial strain with a net income margin of -2,066.55% and negative cash flow from operations of $459.61 million in 2025. Despite this, analyst consensus remains optimistic with a $13.00 price target, and recent news highlights potential long-term growth from SMR technology commercialization and partnerships like ENTRA1.
The outlook is highly speculative; significant upside exists if NuScale successfully commercializes its reactors by the 2030s, but near-term risks include persistent losses, high cash burn, and execution hurdles. Investors face substantial volatility with the stock near its 52-week low, requiring high risk tolerance for potential multi-bagger returns amid operational and competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
